Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pseudouridine synthase 1 (PUS1) is an enzyme responsible for the post-transcriptional modification of RNA, specifically catalyzing the isomerization of uridine to pseudouridine (Ψ) in tRNA at positions 38 to 40 and, in some species, in mRNA. PUS1 belongs to the pseudouridine synthase family of enzymes, which play ubiquitous roles in RNA processing and gene expression regulation. This modification affects RNA structure and RNA–protein interactions, impacting translation and cellular function. In humans, defects or mutations in PUS1 cause mitochondrial myopathy and sideroblastic anemia (MLASA), underscoring its essential role in mitochondrial function and erythropoiesis. The enzyme acts independently (as a stand-alone synthase) and utilizes specific sequence and structural motifs within target RNAs for substrate recognition and modification[1][2]. No approved drugs are known to modulate PUS1 directly.
Catalyzes the isomerization of uridine to pseudouridine at specific positions in tRNA and, in some cases, mRNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pseudouridine synthase 1 (PUS1).